I'm hoping, and it seems reasonable to me, that once the trial is unblinded Dr. Patterson, Amarex, and whomever else is involved in the analysis and compilation of the data can immediately get to work on the patient data they already have. As the end of the month approaches they then would only be waiting to analyze and add to the findings the results of the final few patients as they complete their 2 or 4 week regimens. Assuming they can get ahead of things before the end of the month I'm optimistic that submission for approval would happen quite quickly after getting the last patient's data. How long the FDA takes to review and respond is a whole nother guess though.